A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML

A Comparison of High-Dose Cytarabine During Induction Versus Consolidation Therapy in Newly Diagnosed AML

Abstract. The proportion of patients with acute myeloid leukemia (AML) cured is increased by administering high-dose cytarabine (HiDAC). It remains uncertain whether to administer HiDAC as induction or consolidation, and whether ≥1 cycle of HiDAC is required. Our retrospective study of 416 adult AML...

Full description

Bibliographic Details
Main Authors: Anthony P. Schwarer, Jason Butler, Kathryn Jackson, Ashanka Beligaswatte, Louisa Martin, Glen Kennedy, Zantomio Daniela, Ian Lewis, Devendra Hiwase, Joel Wight, Simon He, Andrew Grigg, Kirk Morris, Peter Mollee, Paula Marlton
Format: Article
Language:English
Published: Wolters Kluwer 2018-12-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000158

Internet

http://journals.lww.com/10.1097/HS9.0000000000000158

Similar Items